LRRK2 and Parkinson disease: In studies of subjects with Parkinson’s disease, LRRK2 (leucine-rich repeat kinase 2) mutations, or Dopa-responsive dystonia, they produced unique insights into the potential differential losses of DA synthesis and storage, DAT binding, and VMAT2 binding related to disease progression [71], age of onset and severity of disease [72], compensatory processes [73,74], and sensitivity to dopamine depletion [66].